Other Assets

Other assets consist of the following at December 31:



	2012							2011							Weighted Average Life
	Cost		Accumulated Amortization			Net		Cost		Accumulated Amortization			Net		Weighted Average Life
Intangible assets:
Technology licenses	$	44,548	$	(41,413	)	$	3,135	$	44,827	$	(40,860	)	$	3,967	12
Patents	6,503		(3,956		)	2,547		6,503		(3,306		)	3,197		10
Customer relationships	17,649		(8,259		)	9,390		17,649		(6,901		)	10,748		13
Goodwill	29,990		—			29,990		29,990		—			29,990
Other	3,230		—			3,230		1,161		—			1,161
Total intangible assets	101,920		(53,628		)	48,292		100,130		(51,067		)	49,063
Available-for-sale investments	—		—			—		30,113		—			30,113
Notes receivable from affiliate	1,192		—			1,192		2,383		—			2,383
Turnaround costs	83,726		(54,666		)	29,060		86,728		(57,175		)	29,553		5
Debt issuance costs	19,219		(8,149		)	11,070		20,628		(8,989		)	11,639		13
Other, net	27,736		(10,351		)	17,385		22,502		(9,678		)	12,824		4
Other assets, net	$	233,793	$	(126,794	)	$	106,999	$	262,484	$	(126,909	)	$	135,575

Amortization expense on other assets of $25,131, $22,812 and $25,142 is included in the consolidated statements of operations for the years ended December 31, 2012, 2011 and 2010, respectively.

Scheduled amortization of intangible assets for the next five years is as follows: $3,298, $2,707, $2,707, $2,652 and $1,811 in 2013, 2014, 2015, 2016 and 2017, respectively.

Goodwill

The annual impairment test for the recorded goodwill was performed as of October 31, 2012. The Company's impairment test indicated that its goodwill was not impaired. The fair value of the Olefins segment, the reporting unit assessed, was calculated using both a discounted cash flow methodology and a market value methodology. The discounted cash flow projections were based on a nine-year forecast, from 2013 to 2021, to reflect the cyclicality of the Company's olefins business. The forecast was based on (1) prices and spreads projected by IHS Chemical, a chemical industry organization offering market and business advisory services for the chemical market, for the same period, and (2) estimates by management, including our strategic and operational plans. Other significant assumptions used in the discounted cash flow projection included sales volumes based on current capacities. The future cash flows were discounted to present value using a discount rate of 8.8%.

The significant assumptions used in determining the fair value of the reporting unit using the market value methodology include the determination of appropriate market comparables and the estimated multiples of EBITDA a willing buyer is likely to pay.

Under the discounted cash flow methodology, even if the fair value of the Olefins segment decreased by 20%, the carrying value of the Olefins segment would not exceed its fair value.

Available-for-sale Investments

There were no available-for-sale investments reflected in other assets, net in the consolidated balance sheet at December 31, 2012 as the Company completed the liquidation of its holdings of equity securities during the third quarter of 2012. The proceeds from sales of available-for-sale equity securities and the gross realized gains included in the consolidated statements of operations are reflected in the table below. The cost of securities sold was determined using the specific identification method.



	Year Ended December 31,
	2012
Proceeds from sales of available-for-sale equity securities	$	47,655
Gross realized gains	$	16,429

Investments reflected in other assets, net at December 31, 2011 was $30,113. These investments in equity securities were classified as available-for-sale. The cost, gross unrealized gains, gross unrealized losses and fair value of the Company's available-for-sale investments at December 31, 2011 were as follows:



	December 31, 2011
	Cost		Gross Unrealized Gains		Gross Unrealized Losses ⁽¹⁾			Fair Value
Available-for-sale equity securities	$	28,265	$	1,981	$	(133	)	$	30,113

______________________________


(1)	All unrealized loss positions were held at a loss for less than 12 months.

As of December 31, 2011, an unrealized gain of $1,185, net of income tax expense of $663, was recorded in accumulated other comprehensive income. See Note 12 for the fair value hierarchy of the Company's available-for-sale securities.